GuidelineJournal of the American Society of Hypertension : JASH
Combination therapy in hypertension.
Guideline in Journal of the American Society of Hypertension : JASH. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 66 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
66 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Exploring the benefits and safety of combining nebivolol and valsartan for managing hypertension: a systematic review.BMC cardiovascular disorders · 2026Pooled it
- Efficacy of Single-Pill, Triple Antihypertensive Therapy in Patients with Uncontrolled Hypertension: A Systematic Review and Meta-analysis.High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension · 2022Pooled it
- Long-term and recent trends in hypertension awareness, treatment, and control in 12 high-income countries: an analysis of 123 nationally representative surveys.Lancet (London, England) · 2019Pooled it
- Oral antihypertensive therapy for severe hypertension in pregnancy and postpartum: a systematic review.BJOG : an international journal of obstetrics and gynaecology · 2014Pooled it
- Additivity of nebivolol/valsartan single-pill combinations versus other single-pill combinations for hypertension.Journal of clinical hypertension (Greenwich, Conn.) · 2018Trial
- Comparison of olmesartan combined with a calcium channel blocker or a diuretic in elderly hypertensive patients (COLM Study): safety and tolerability.Hypertension research : official journal of the Japanese Society of Hypertension · 2015Trial
- Combination therapy of hypertension in the elderly: a subgroup analysis of the Combination of OLMesartan and a calcium channel blocker or diuretic in Japanese elderly hypertensive patients trial.Hypertension research : official journal of the Japanese Society of Hypertension · 2015Trial
- Combinations of olmesartan and a calcium channel blocker or a diuretic in elderly hypertensive patients: a randomized, controlled trial.Journal of hypertension · 2014Trial
- Different aspects of sartan + calcium antagonist association compared to the single therapy on inflammation and metabolic parameters in hypertensive patients.Inflammation · 2014Trial
- Olmesartan/amlodipine/hydrochlorothiazide in obese participants with hypertension: a TRINITY subanalysis.Journal of clinical hypertension (Greenwich, Conn.) · 2013Trial
- Combined olmesartan, amlodipine, and hydrochlorothiazide therapy in randomized patients with hypertension: a subgroup analysis of the TRINITY study by age.Drugs & aging · 2013Trial
- Safety and efficacy of aliskiren/amlodipine/hydrochlorothiazide triple combination in patients with moderate to severe hypertension: a 54-week, open-label study.Journal of clinical hypertension (Greenwich, Conn.) · 2012Trial
- Olmesartan/amlodipine/hydrochlorothiazide in participants with hypertension and diabetes, chronic kidney disease, or chronic cardiovascular disease: a subanalysis of the multicenter, randomized, double-blind, parallel-group TRINITY study.Cardiovascular diabetology · 2012Trial
- Long-term efficacy and safety of triple-combination therapy with olmesartan medoxomil and amlodipine besylate and hydrochlorothiazide for hypertension.Journal of clinical hypertension (Greenwich, Conn.) · 2012Trial
- Combination therapy as initial treatment for newly diagnosed hypertension.American heart journal · 2011Trial
- Ambulatory blood pressure response to triple therapy with an angiotensin-receptor blocker (ARB), calcium-channel blocker (CCB), and HCTZ versus dual therapy with an ARB and HCTZ.Vascular health and risk management · 2011Trial
- Fixed-Dose Combinations for Hypertension: Barriers to Use and Opportunities for Health Systems.Journal of clinical hypertension (Greenwich, Conn.) · 2026Article
- Synthesis, characterization,RSC advances · 2026Article
- Chlorogenic acid and gallic acid synergistically reduce hyperglycemia and hyperlipidemia in diabetic BALB/c mice.Scientific reports · 2026Article
- Risk Factors Control After an Acute Coronary Syndrome and Association with Major Adverse Cardiovascular Events: A Single Center Experience in Latin-America.High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension · 2023Article
6 more citing papers are in PubMed but not listed here.
Corrections and comments
- Erratum issued
- Reprinted as
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The goal of antihypertensive therapy is to abolish the risks associated with blood pressure (BP) elevation without adversely affecting quality of life. Drug selection is based on efficacy in lowering BP and in reducing cardiovascular (CV) end points including stroke, myocardial infarction, and heart failure. Although the choice of initial drug therapy exerts some effect on long-term outcomes, it is evident that BP reduction per se is the primary determinant of CV risk reduction. Available data suggest that at least 75% of patients will require combination therapy to achieve contemporary BP targets, and increasing emphasis is being placed on the practical tasks involved in consistently achieving and maintaining goal BP in clinical practice. It is within this context that the American Society of Hypertension presents this Position Paper on Combination Therapy for Hypertension. It will address the scientific basis of combination therapy, present the pharmacologic rationale for choosing specific drug combinations, and review patient selection criteria for initial and secondary use. The advantages and disadvantages of single pill (fixed) drug combinations, and the implications of recent clinical trials involving specific combination strategies will also be discussed.
Indexed as
Identifiers
20374950What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.